

Special Issue

Recent Advances in Antiphospholipid Syndrome

Message from the Guest Editor

Dear colleagues, Although guidelines of international society of thrombosis and haemostatis (ISTH) and America rheumatology association are available from several years to suggest diagnosis and treatments for primary and secondary antiphospholipid syndrome several issues are frequently debated in the daily clinical practice. Immunomediated thrombosis recognises different pathophysiological mechanisms from traditional arterial and venous thrombosis and new pathophysiological mechanisms are recently described. Furthermore, clinical presentation differs in young patients or adult patients, and also, therapeutic support offers different outcomes in patients with primary or secondary antiphospholipid syndrome. Furthermore, the follow-up strategy of carriers of asymptomatic abnormal values of antiphospholipid antibodies is still debated. Therefore, this Special Issue is dedicated to scholars that may offer their clinical and laboratory experience in the management of clinical overt antiphospholipid syndrome or asymptomatic carriers of antiphospholipid antibodies. We think that this is still an intriguing clinical issue, and we hope that scholars around world agree.

Guest Editor

Dr. Pierpaolo Di Micco
UOC Medicina, Fatebenefratelli Hospital of Naples, 80131 Naples, Italy

Deadline for manuscript submissions

closed (30 June 2025)



Immuno

an Open Access Journal
by MDPI

Impact Factor 2.5
CiteScore 3.7



mdpi.com/si/175428

Immuno
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
immuno@mdpi.com

[mdpi.com/journal/
immuno](https://mdpi.com/journal/immuno)





Immuno

an Open Access Journal
by MDPI

Impact Factor 2.5
CiteScore 3.7



[mdpi.com/journal/
immuno](https://mdpi.com/journal/immuno)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Toshihiko Torigoe
Department of Pathology, Sapporo Medical University School of
Medicine, S-1, W-17, Chuo-ku, Sapporo 060-8556, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,
and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 28.8 days after
submission; acceptance to publication is undertaken in 2.7
days (median values for papers published in this journal in
the second half of 2025).